Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension

Ophthalmology

Volumn 121, Issue 12, 2014, Pages 2348-2355

  Aung, Tin ^a,b   Laganovska, Guna ^c   Hernandez Paredes, Tania Josefina ^d   Branch, James D ^e   Tsorbatzoglou, Alexis ^f   Goldberg, Ivan ^g,h,i  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^d Oftalmica PAHE   (Mexico)

^e Private Practice   (United States)

^f Plant and Soil Protection Directorate   (Hungary)

^g UNIVERSITY OF SYDNEY   (Australia)

^h SYDNEY EYE HOSPITAL   (Australia)

ⁱ Eye Associates   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; BRIMONIDINE PLUS BRINZOLAMIDE; BRINZOLAMIDE; ANTIHYPERTENSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; EYE DROPS; QUINOXALINE DERIVATIVE; SULFONAMIDE; THIAZINE DERIVATIVE;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; ASTHENOPIA; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; DYSGEUSIA; EYE ALLERGY; EYE DISCOMFORT; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYELID EDEMA; FEMALE; FOREIGN BODY REACTION; HEADACHE; HUMAN; HYPEREMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NOSE DISEASE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; XEROSTOMIA; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GLAUCOMA, OPEN-ANGLE; MIDDLE AGED; OCULAR HYPERTENSION;

AGED; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUINOXALINES; SULFONAMIDES; THIAZINES;

EID: 84922222298     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.06.022     Document Type: Article

References (18)

1. European Glaucoma Society Terminology and Guidelines for Glaucoma 3rd ed. 2008 Editrice DOGMA Savona, Italy 122 145 Available at: http://www.eugs.org/eng/EGS-guidelines.asp Accessed June 9, 2014
2. C.A. McCarty, B.N. Mukesh, and T.E. Kitchner Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project J Glaucoma 17 2008 372 377
3. C. Vorwerk, U. Thelen, P. Buchholz, and F. Kimmich Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice Curr Med Res Opin 24 2008 1295 1301
4. P.P. Lee, J.G. Walt, and T.H. Chiang A gap analysis approach to assess patient persistence with glaucoma medication Am J Ophthalmol 144 2007 520 524
5. E.J. Higginbotham, J. Hansen, and E.J. Davis Glaucoma medication persistence with a fixed combination versus multiple bottles Curr Med Res Opin 25 2009 2543 2547
6. E.J. Higginbotham, K.W. Olander, E.E. Kim United States Fixed-Combination Study Group Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study Arch Ophthalmol 128 2010 165 172
7. G. Katz, H. Dubiner, and J. Samples Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2% JAMA Ophthalmol 131 2013 724 730
8. Q.H. Nguyen, M.G. McMenemy, and T. Realini Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2% J Ocul Pharmacol Ther 29 2013 290 297
9. J.T. Whitson, T. Realini, and Q.H. Nguyen Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension Clin Ophthalmol 7 2013 1053 1060
10. T. Realini, Q.H. Nguyen, G. Katz, and H. Dubiner Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies Eye (Lond) 27 2013 841 847
11. N.M. Kerr, H.Y. Patel, and S.S. Chew Patient satisfaction with topical ocular hypotensives Clin Experiment Ophthalmol 41 2013 27 35
12. B. Sleath, A.L. Robin, and D. Covert Patient-reported behavior and problems in using glaucoma medications Ophthalmology 113 2006 431 436
13. F. Djafari, M.R. Lesk, and P.J. Harasymowycz Determinants of adherence to glaucoma medical therapy in a long-term patient population J Glaucoma 18 2009 238 243
14. C.M. Olthoff, J.S. Schouten, B.W. van de Borne, and C.A. Webers Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review Ophthalmology 112 2005 953 961
15. S.S. Chrai, M.C. Makoid, S.P. Eriksen, and J.R. Robinson Drop size and initial dosing frequency problems of topically applied ophthalmic drugs J Pharm Sci 63 1974 333 338
16. P.J. Pisella, P. Pouliquen, and C. Baudouin Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication Br J Ophthalmol 86 2002 418 423
17. E.J. Higginbotham Considerations in glaucoma therapy: fixed combinations versus their component medications Clin Ophthalmol 4 2010 1 9
18. R. van der Valk, C.A. Webers, and J.S. Schouten Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials Ophthalmology 112 2005 1177 1185